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ABSTRACT
Iron and folic acid supplementation plays a major role in prevention and control of iron deficiency anaemia 
in antenatal care. In South Africa, although all pregnant women receive iron, folate and calcium 
supplementation throughout pregnancy, anaemia is still common.  Low adherence may be a key contributor 
to the ineffectiveness of supplementation programs.Therefore, this study was conducted to examine 
adherence to prophylactic iron supplementation during the antenatal period. An observational clinical study 
was conducted in a regional hospital from January- December 2016. Women (n=100 HIV uninfected and 
n=100 HIV infected) were recruited and subdivided into three groups: (a) 1st attendees ≤ 34 weeks (n=33), 
(b) 34-36 weeks (n =34) and (c) ≥ 37 weeks /birth (n=33) respectively. A structured questionnaire was used 
for data collection. 
Data were coded and computed onto an excel sheet for statistical analysis using SPSS software.
 Data from women (n = 24) from 1st visit attendees ≤ 34 weeks and 34-36 weeks subgroups indicated that 
pill count and self-reported data reflected 50% adherence and 46% non-adherence, being higher in the HIV 
infected women (75%). Nausea was the commonest side effect in all trimesters (79, 2%). Adherence 
(27.8%) and non-adherence (72.1%) to iron, folic acid and calcium supplementation were observed in 176 
(88%) women. 
Promoting essential strategies on the importance of consumption and effectiveness of iron prophylactic 





1.0 Overview of Iron Prophylactic Therapy 
Prophylactic iron, folic acid and multivitamins are prescribed routinely for all antenatal attendees in 
maternity health facilities. However, the effect of supplementation to all antenatal women remains   
controversial (Osungbade et al., 2012). There is evidence that providing prophylactic iron, folate and 
multivitamin supplementation prior to pregnancy is of benefit. Many women enter pregnancy with depleted 
iron stores (Cantor et al., 2015). Nonetheless, there is uncertainty of the value of supplementation to all 
pregnant women irrespective of their haemoglobin levels (Parkkali et al., 2013). Patient adherence to “pill 
taking” remains unknown.  Apart from antiretroviral drugs, HIV infected pregnant women have an added 
burden of further supplementation of iron, folate, calcium and multivitamins.
1.1 Background and Literature
Iron deficiency is the most widespread pathologic cause of anaemia in pregnancy (Cantor et al., 2015). It 
is the most common nutrient deficiency internationally, amongst pregnant women and children, especially 
in low and middle-income countries (Taye et al., 2015). Iron is an essential nutrient, which is necessary for 
haemoglobin synthesis (Millman, 2011). Its requirement increases during pregnancy and is not adequately 
supplied through the regular diet, especially in low and middle-income countries (LMIC). Furthermore, a 
loss of appetite during pregnancy can worsen the demand for iron (Mithra et al., 2014). Therefore, the most 
appropriate mass intervention to reduce incidence of anaemia is the provision of prophylactic iron and folic 
acid to all pregnant women    throughout pregnancy (Mithra et al., 2014). Folic acid is provided to prevent 
neural tube defects and macrocytic anaemia (Hodgetts et al., 2014). There is strong evidence that folic acid 
has resulted in a significant decrease in neural tube defects especially when started two /three months prior 
to pregnancy and during the first trimester of pregnancy when the fetal neural system developes (Hodgetts 
et al., 2014).
 A decrease in iron stores during pregnancy is accompanied by a significant rise in the reticulocyte count 
and eventually an increase in erythropoiesis in the bone marrow (Ehiaghe et al., 2014). Therefore, the 
reticulocyte count can be used to monitor progress after iron supplementation. In pregnancy the 
physiological demands of a growing fetus, changes in blood and red cell volume,
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vomiting and increasing nutrient demands exacerbates the need for iron supplementation (Millman, 2011) 
. 
It has been shown that iron deficiency is linked with serious long-term consequences in children, such as 
increased vulnerability, to infections, poor physical growth, poor appetite, retardation of cognitive and 
psychomotor development and cardiac failure (Mamabolo and Alberts, 2014). 
The efficacy and the success of intervention depends on the compliance to the Iron-folic acid tablet intake. 
Compliance describes the degree to which a patient accurately follows a medical instruction. Many experts 
believe that one of the major reasons that national iron supplementation programs have failed is women’s 
non-adherence to pill taking. Other factors that have not been studied extensively include health systems 
(Mithra et al., 2014). Non-adherence is defined as missing two or more doses repeatedly. Although 
adherence to iron- folic acid therapy is crucial, there is uncertainty affected by several social and 
demographic factors (Mithra et al., 2014). There is evidence that older women and those with a history of 
miscarriage are more likely to achieve greater adherence (Nwaru et al., 2015). Furthermore, it has been 
shown that adherence depends on the woman’s behaviour during antenatal period (Nwaru et al., 2015). In 
addition, there is a lack of evidence that the use of antiretroviral drugs during pregnancy increases the 
severity of anaemia (Nandlal et al., 2014). The use of these drugs and other medications may increase the 
level of non-adherence to iron prophylactic therapy during antenatal period (Nandlal et al., 2014). In 
addition, there is a limited focus regarding the use of other medications concurrently with iron supplements. 
1.1.1. Iron 
Iron is one of the most important minerals needed by the human body. It is found in every cell and is 
essential for haemoglobin synthesis (Milman, 2011). The human body has iron stores ready to replace iron 
that is lost but low iron levels over a long time may result in iron deficiency anaemia. Symptoms of low 
iron levels include irritability, lack of energy, weight loss, dizziness, headache and shortness of breath. 
Pallor of the mucus membranes such as the tongue and spoon shaped nails are two of the physical signs of 
low iron concentrations. 
The best sources of iron are: eggs, liver, lean red meat, oysters, poultry, iron-fortified cereals, dried fruits, 
dried beans, fish, salmon, tuna, and whole grains. However, iron from vegetables, fruits and supplement is 
difficult for the body to absorb (Iron in diet. University of Maryland Medical Centre;  
http://umm.edu/health/medical/ency/articles/ (accessed 0n 01 July 2016; pp 1-5). These sources include 
dried fruits, legumes, seeds, vegetables, and whole grains. Iron absorption is increased with foods rich in 
vitamin C. 
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Foods that curb iron absorption contain substances that inhibit dietary iron utilisation e.g., commercial black 
and pekoe teas. Excessive consumption of iron may exacerbate a genetic disorder known as 
hemochromatosis. This disorder affects iron absorption and leads to iron overload in the body. However, it 
is not likely for a person to ingest too much iron (Iron in diet. University of Maryland Medical Centre; 
http://umm.edu/health/medical/ency/articles/iron-in-diet (accessed 0n 01 July 2016; pp 1-5).  
Table 1.0: Recommendation for daily iron requirement (The Food and Nutrition Board at the 









9 to 13 years 8mg Younger than 6 
months
0.27mg 9 to 13 years 8mg
14 to 18 years 15mg 7 months to 1 
year
11mg 14 to 18 years 11mg
19 to 50 years 18mg 1 to 3 years 7mg 19 & older 8mg









Iron metabolism is essential for understanding diseases of iron such as iron deficiency anaemia and iron 
overload (WHO, 2015). Iron importation can take place through endocytosis of transferrin receptor 1 or 
through ferrous iron importers DMT1 and ZIP14, which needs the activity of iron reductases such as 
STEAP2, SDR2 and Dcytb (WHO, 2015). Intracellular iron can be stored in ferritin, used for protein 
biosynthesis, produce reactive oxygen species (ROS) and control transcription using iron-responsive 
element-binding proteins (IRP1/2). Export occurs through ferropoetin, frequently aided by hephastin (Hp) 
and ceruloplasmin (Cp), and reserved by hepcidin (WHO, 2015). 
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Figure: 1.0 Diagram showing a generalised view of cellular iron homeostasis in humans (adapted from 
human iron metabolism (https://en.wikipedia.org/wiki/human iron metabolism, accessed on 01 July,2016: 
pp 1-11)
1.1.3. Haemoglobin
Haemoglobin is a molecule comprised of four subunits. Each subunit has an iron containing pigment (heme) 
and a protein (globulin).  The subunits consist of two types, alpha and beta and each gram of subunit can 
take 1.34 ml of oxygen. Therefore, the oxygen carrying ability of blood is directly proportional to its 
haemoglobin concentration. Because some cells may contain more haemoglobin than others, the number of 
blood cells cannot indicate blood oxygen content. Haemoglobin determination is used to screen for 
anaemia, to classify the severity of anaemia, and to aid in evaluating the patient’s response to anaemia 
therapy). Total haemoglobin content is lowered by the blood loss and bone marrow suppression, which 
reduces total red blood cell count (RBC). Haemoglobin levels are also lowered in patients who have 
abnormal types of haemoglobin or haemoglobinopathy (Haemoglobin - Complete Blood Count – 
http://www.rnceus.com/cbc/cbchg.html 2013; accessed 1 July 2013: 1-2). Red blood cells with abnormal 
types of haemoglobin are often brittle and or destroyed easily in the vascular system. Some patients have 
normal red blood cell count but a low haemoglobin level. Normal Haemoglobin values are: Adult 
(males):13.5–17g/dl, females: 12-15g/dl, Pregnancy: 11- 12g/dl, Newborn: 14-24g/dl. 77 of this value is 




Ferritin is a protein that originates from cells that stores iron for later use. The Ferritin test measures the 
amount of iron in the blood. The amount of ferritin (serum ferritin level) is directly linked to the amount of 
iron stored in human body. Low ferritin levels even within normal ranges may indicate inadequate iron. 
However, normal value ranges may differ slightly among different laboratories. Normal ranges are, Male: 
20 to 200ng/ml, female: 15 to 150ng/ml. (Gersten, 2016). Ferritin levels can rise with inflammatory 
disorders and a higher than normal level may be due to too much iron in the body, frequent transfusion of 
packed red blood cells and alcoholic liver disease. A lower than normal level may be caused  by heavy 
menstrual bleeding, high physiological demand during pregnancy, intestinal conditions that cause poor 
absorption of iron, iron deficiency anaemia and long term digestive tract bleeding (Gersten, 2016).
1.1.5. Reticulocyte
Reticulocytes are defined as immature red cells seen in the peripheral blood that contains at slightest two 
dots of reticulin material that reflect with new methylene blue (NMB) in their cytoplasm (a case of iron 
deficiency anaemia; http://www.meddean.luc.edu/lumen/meded/mech/cases/case7/ accessed 09June 2016: 
pp 1-7). More forms that are immature have various dots and tiny networks of skeins of bluish material. 
These remnants are residual ribosomal RNA used for haemoglobin synthesis in the developing erythrocyte. 
The RNA is thinly distributed to form networks on Wright’s stain; a supravital stain causes precipitation 
and aggregation of the RNA and creates the dots and skeins of reticulin. RNA containing red cells are 
usually greyish on Wright’s stain and contrast well with mature, ortho-chromic or pink red cells, providing 
an indication to the presence of reticulocyte reaction (a case of iron deficiency anaemia; 
http://www.meddean.luc.edu/lumen/meded/mech/ accessed; 09June  2016: pp 1-7). Three ways to express 
reticulocyte response are: reticulocyte count, corrected reticulocyte   count and absolute reticulocyte count. 
They are counted as the number of NMB-reactive cells per 1,000 red cells and expressed as a percentage 
of reticulocytes (absolute number per 100 red cells). A reticulocyte count assists in categorising anaemia 
into hypo or hyper-proliferative types. The normal count is 0.5-1.5% (a case of iron deficiency anaemia; 
http://www.meddean.luc.edu/lumen/meded/mech/cases/case7/: accessed 09 June 2016: pp 1-7) The 
hypoproliferactive type indicates reduced reticulocytes, the bone marrow not able to produce requisite 
number of red blood cells (RBC’s) and lack of essential substances (iron, B12, and folate). 
The hypeproliferactive type indicates increased reticulocytes, the cause of anaemia being outside the bone 
marrow (haemolytic anaemia, haemorrhage and post anaemia treatment), reduced survival of
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RBC’s and a   normal bone marrow that responds effectively by increasing the output.  A RBC has a lifespan 
of about 120 days and less than 1% is replaced every day (a case of iron deficiency anaemia; 
http://www.meddean.luc.edu/lumen/meded/mech/cases/case7/anaemia.html: accessed 09June 2016: pp 1-)
Figure: 1.1: Diagram illustrating iron absorption, storage and recycling. (adapted from human iron 
metabolism (https://en.wikipedia.org/wiki/human iron metabolism, accessed on 01 July,2016:)
1.2. Iron deficiency anaemia
Iron deficiency (ID) is a worldwide problem with infants and their mothers been more vulnerable to both 
the development and the consequences of iron deficiency. In concert with pregnancy, the crucial period of 
“1000 days” is associated with adverse effects later in life, such as increased risk of non-communicable 
diseases, as well as decreased capability and economic productivity (Burke et al., 2014). Furthermore, 
entering pregnancy with low iron status results in serious life consequences to both mother and the infant. 
It is considered to be the main common cause of iron deficiency anaemia (IDA) in pregnancy (Mithra et 
al., 2014). Iron deficiency in pregnancy is due to the fact that iron stores are inadequate to meet the 
increasing demands of pregnancy. It has been reported that IDA is associated with a rise in maternal 
mortality, stillbirths, low birth weights babies, neonatal sepsis and intrauterine growth restriction (Tunkyi 
and Moodley, 2016). 
Anaemia   is a public health problem affecting both low and high-income countries resulting with major 
outcomes on human health as well as social and economic development (Bekele at al., 2016). The World 
Health Organization (WHO) defines anaemia as a haemoglobin (HB) concentration of ≤ 11g/dl (Tunkyi 
and Moodley, 2016). Furthermore, IDA is characterised by microcytic, hypochromic erythrocytes and 
decreased iron stores. A deficiency in iron is the most common cause of microcytic
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anaemia. A patient with less than normal microcytic and hypochromic cells is deficient to iron. Therefore 
the mean cell volume (MCV), mean cell haemoglobin (MCH) and mean cell haemoglobin concentration 
(MCHC) are  significant indicators/markers of  IDA and are used to diagnose and  observe recovery  
(Erhabor et al., 2013).
1.2.1. Anaemia Prevalence
The World Health Organization (WHO) estimates anaemia prevalence at 9% in high income countries and 
43% in LMIC , 47% in children younger than 5 years, 42% in pregnant women, and 30% in non-pregnant 
women aged 15-49 years with Africa and Asia accounting for more than 85% of the total anaemia burden 
in high risk groups (Bekele et al., 2016). A study conducted in the United States of America (USA) 
concluded that prevalence of iron deficiency in that country was approximately 18%. (Bekele et al., 
2016).The rates of iron deficiency increases across the trimesters of pregnancy from 6.9% to 14.3% to 
28.4% (Cantor et al., 2015). Furthermore, anaemia in pregnancy is linked with substantial health and 
economic cost implications. The Saving Mothers Report (2010-2013) revealed that 40% of maternal deaths 
in South Africa (SA) were associated with anaemia, irrespective of micronutrient (prophylactic iron, folic 
acid and multivitamins) supplementation. Anaemia prevalence at first antenatal visit in a study conducted 
in South Africa reports 42.7%. These results are consistent with prevalence rates of 40% in Kenya, 38.2% 
in Ethiopia and 47.4% in Tanzania (Tunkyi and Moodley, 2016). Anaemia ranges from mild, moderate and 
severe and the WHO states that the haemoglobin level in pregnancy at 10.0-10.9g/dl is (mild anaemia), 7-
9.9 g/dl (moderate anaemia) and ≤7g/dl (severe anaemia). Iron deficiency anaemia detected early in 
pregnancy is linked to loss of energy and low iron intake resulting to a decrease in gestational weight gain 
over the entire pregnancy (Panda et al., 2015). 
1.2.2 Human immunodeficiency virus (HIV) infection and Anaemia in pregnancy
Sub-Saharan countries have a high prevalence of anaemia associated with HIV infection. However, there 
is a lack of data on anaemia amongst South African pregnant women. The prevalence of anaemia in SA is 
19.7% (Van Bogaert, 2006). 
Furthermore, prevalence from African countries show varying rates possibly reflecting varying sample  
sizes of the study populations, geographical area (rural or urban), rates of parasitic infestations and levels 
of education (Tunkyi and Moodley, 2016). In 2012, The Saving Mothers Report in South Africa stated that 
HIV infection (70%) and anaemia (30%) were the commonest conditions amongst pregnant women who 
died during pregnancy and in the puerperium phase
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(Nandlal et al., 2014). The consequences of the effect of anaemia in association with HIV infection on both 
maternal and birth phase is unclear.
1.3. Iron and Folic supplementation
Oral iron supplementation clinically prevents iron deficiency in pregnancy (Jasti et al., 2005). According 
to WHO recommendations daily oral iron and folic acid supplementation is recommended to reduce the 
risk of low birth weight, maternal anaemia and iron deficiency in all antenatal care clinics (WHO guidelines, 
2012). One of the national health objectives designed by the U.S Department of Health and Human Services 
was to decrease anaemia in the third trimester to 20% by the year 2010. Prevention for average risk 
populations includes sufficient dietary iron intake and oral low dose (30mg) iron supplements early in 
pregnancy and suggested prophylaxis for iron deficiency anaemia (IDA) in high risk populations is 
elemental iron of 60 to 100mg daily. Prenatal screening for IDA was reviewed by the U.S. Preventive 
Services Task Force (USPSTF) in 2006 and recommended routine screening on the basis of fair quality 
evidence. There was evidence that treating asymptomatic IDA in pregnancy results in moderate health 
benefits (Cantor et al., 2012). The most appropriate mass intervention for iron supplementation is to 
administer iron along with folic acid in a tablet form to all pregnant women. The aim is to improve the level 
of haemoglobin for anaemia to be reduced as highly as possible at term (Mithra et al., 2014). However, in 
public health settings the supply of oral iron therapy to pregnant women has been less effective.
1.3.1. Oral Ferrous Sulphate
Ferrous sulphate is supplied to all antenatal settings. It is a white, circular, biconvex, sugar- coated tablet 
used for prevention and treatment of iron deficiency anaemia. Each tablet contains 200mg dried ferrous 
sulphate equivalent to 65mg ferrous iron. It originates from a group of medicines called iron supplements 
whose work is to replace lost iron.  There are products that increases or decrease the absorption of iron. For 
example, it is reduced with drinking tea, coffee, milk, eggs and wholegrain and increases with meat products 
containing high levels of vitamin C. Like any other medication, ferrous sulphate can cause side effects 
which are constipation, diarrhoea, abdominal pain and “blackened/dark stools” (Patient information leaflet: 
ferrous sulphate 200mgms {28 pack} https://www.medicines.org.uk/emc/medicine/18081 accessed 05 July 
2016 pp 1-4). 
1.3.2. Oral Folic Acid
Folic acid is highly significant for the foetal development, as it can decrease the incidence of spinal bifida 
caused by neural tube defects (NTDs). A recommendation by the department of health states
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that women should take a daily supplement of 400 micrograms of folic acid while they are trying to fall 
pregnant, and this dose should continue for the first 12 weeks of pregnancy for baby’s spine to develop 
(Hodgetts et al., 2014). Dietary sources of folic acid consist of green leafy vegetables, brown rice, granary 
bread, and breakfast cereals prepared with folic acid (Health questions: Why do I need Folic Acid in 
pregnancy ?  http://www.nhs.uk/chq/pages/913.aspx?categoryid=54 accessed 05 July 2016). It is not 
possible to get folic acid from food. Therefore, it is important to get it from taking supplements. An exact 
amount of folic acid is contained in each tablet and is also safe to use after 12 weeks (Health questions: do 
I need Folic Acid in pregnancy ?  http://www.nhs.uk/chq/pages/ accessed 05 July 2016). However, there is 
a high rate of unplanned pregnancy especially in low-income countries. Therefore, folic acid is supplied to 
all antenatal attendees from the first clinic visit until delivery. In addition in many countries including South 
Africa, bread a staple food is fortified with folia acid. Furthermore, all pregnant women in South Africa 
receive folia acid alone or in combination with folic acid (pregamal) tablets. 
1.3.3. Oral Calcium
Calcium is a rich mineral that is essential for many various processes, such as bone information, muscle 
contraction, and enzyme and hormone functioning. Most of the body’s calcium originates in bones and 
teeth and about 1% is present in the intracellular structures, cell membranes and extracellular fluids (WHO 
guidelines, 2012). Some studies have revealed that calcium supplementation during pregnancy has a 
significant effect on reducing the risk of pre-eclampsia (WHO guidelines, 2012). Insufficient consumption 
of this nutrient by pregnant women may result in adverse effects to both the mother and the fetus. However, 
too much consumption of calcium may enhance the risk of urinary stones and urinary tract infection and 
absorption of other essential micronutrients might be reduced. The WHO in conjunction with the Food and 
Agriculture Organization reports that a dietary intake of 1200 mg per day is recommended for pregnant 
women (WHO guidelines, 2012). In addition, for the purpose of WHO guidelines, two systematic reviews 
were combined to particularly to investigate if calcium supplementation in pregnancy safely improves 
maternal and fetal outcomes. Pre-eclampsia, eclampsia, gestational hypertension with or without 
proteinuria, complications at delivery and any adverse events were considered as critical maternal outcomes 
by the Nutrition Guidance Advisory Group (WHO guidelines, 2012). Furthermore, adverse infant outcomes 
were preterm birth, low birth weight (≤2500 g), stillbirth, death during the neonatal period and any adverse 
effects including small for gestational age or admission to a neonatal care unit (WHO guidelines, 2012). 
Therefore, the WHO suggested a scheme for calcium supplementation in pregnant women. A daily dosage 
of 1.5 – 2.0 g elemental calcium
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should be supplied to all pregnant women, mostly those at higher risk of gestational hypertension (WHO 
guidelines, 2012). The standard clinical practice in South Africa is to give calcium to all antenatal attendees 
until the end of pregnancy (Maternity Care guidelines for clinics and district hospitals in South Africa, 
2016).
1.4. Adherence to Oral Iron Prophylactic Therapy
Limited adherence to iron supplementation is considered to be a main reason for the low effectiveness of 
anaemia prevention programs. Iron supplementation has been a therapeutic approach by tradition, initiated 
after the diagnosis of iron deficiency. Traditionally, iron supplementation was based on therapeutic 
approach of using high dose iron salt or elixir that provides between 60 mg and 180 mg Fe/d (Beard, 2000). 
High doses could cause disturbance in normal absorptive routes and are associated with side effects such 
as gastrointestinal upset, constipation and nausea. 
The 1990 Institute of Medicine Committee and the 1991 Life Sciences Research Office guidelines 
suggested that non- anaemic women be supplied with 30 mg Fe/d starting in the 12th week of pregnancy 
(Beard, 2000). Furthermore, if anaemia is present low plasma ferritin level confirms iron deficiency; the 
daily dose should be 120 or 180 mg Fe/d. It was in 1993 when the Institute of Medicine report recommended 
that women be screened for anaemia at the first antenatal visit (Beard, 2000). In addition, the WHO/Food 
and Agriculture Organization calculated iron requirements for pregnant women based on the need for iron 
that could be absorbed and the need for increased heme iron in the diet. Therefore, the WHO advocated 
supplementation of 60mg Fe/d along with 250 ug folate (Beard, 2000).  Iron deficiency Anaemia prevalence 
and incidence is still significantly high among pregnant women despite routine oral iron supplementation 
(Tunkyi and Moodley, 2016). 
1.4.1. Adherence and side effects
Several studies have shown that side effects appear to be one of the causes of non- adherence to iron 
prophylactic treatment. A study conducted in Bangladesh in 2001 compared side effects of iron 
supplementation and their impact on adherence amongst pregnant women (Hyder et al., 2001). The 
presence of nausea and vomiting reduced the level of adherence in the study group (Hyder et al., 2001). 
Also, a study conducted in Malawi in 2009 reports nausea (43.6%) as the single most important reason for 
non-compliance in the study group (Kalimbira et al., 2009). Studies conducted in India also reports nausea 
and vomiting as the most common side effects observed, accompanied by heartburn, diarrhoea, constipation 
and abdominal pain (Sangwan et al., 2014). Forgetfulness and
12
bad taste were also given as reasons for non-adherence (Panda et al., 2015). The main reason for skipping 
doses is forgetfulness (48.8%) followed by gastritis, constipation, vomiting, and travel (Mithra et al., 2014).
Compliance level is again influenced by age, education, parity, socio – economic status and number of 
clinic visits especially in low and middle-income countries. A study by Sangwan et al., (2014) showed the 
association of age, parity, education, socio – economic status, early registration and number of clinic visits 
were associated with Iron – Folic Acid (IFA) intake. 
Furthermore, a study by Roy et al., (2013) reports influence of education, parity, timing of registration and 
number of antenatal clinic visits were proportional to IFA, whilst age, socio – economic status and family 
type were not directly associated. In contrast, a study by Mithra et al., (2013) has shown that age, socio 
economic status and parity are major contributors to IFA adherence. 
The study adherence in their group was 64.7%, which is similar to the findings (67.9%) by Sangwan et al., 
(2014). These results were again comparable to a study conducted in Senegal in 2008 (Sengwan et al., 
2014). Anaemic women  have a lower level of adherence whereas those above 25yrs and in second 
pregnancy are more compliant (Sengwan et al., 2014). Few studies have addressed the challenges of the 
socio economic climate on iron supplement adherence (Sangwan et al., 2014). 
1.4.2. Pill count 
 A few studies have used the “pill count” to observe adherence of iron – folic acid consumption. A study 
conducted in the United State in 2005 among non – Hispanic white and Non–Hispanic Black women 
revealed that “pill count” is more significant than self- reported compliance (Jasti et al., 2005). Adherence 
was monitored using an electronic counting device to record date and time at which the bottle was opened 
at the time of pill taking. Study groups were unaware of this device. Pill count was more accurate than self- 
reports (Jasti et al., 2005). Another study in Bangladesh utilised a similar method of monitoring pill count 
to record adherence of iron-folic acid adherence (Heyder et al., 2002).
In South Africa, no studies have been conducted on adherence to iron prophylactic supplements during 
pregnancy. African- based studies have revealed that antenatal attendees have complex reasons for not 
taking iron supplements that involves socio-cultural context that intensely shapes one’s behaviour (Sambili 
et al., 2016). Therefore, this study includes other factors that can reduce the level of adherence to iron 
supplements among pregnant women attending antenatal clinic.    
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This study establishes adherence to prophylactic iron supplementation during the antenatal period, in an 
urban setting in South Africa.
1.4.3. Aims and Objectives of the study
The use of iron supplements by pregnant women is still uncertain, therefore the aim of this study is to 
establish adherence to prophylactic iron supplementation during the antenatal period, in an urban setting in 
South Africa.
The specific objectives include assessing adherence to prophylactic iron supplementation and determination 
of haemoglobin levels; reticulocyte count and serum ferritin after oral supplementation in HIV uninfected 
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SYNOPSIS
This study set out to establish whether antenatal attendees adhere to prophylactic iron 




To assess adherence to prophylactic iron supplementation during the antenatal period in 
South Africa.
Methods: 
An observational clinical study was conducted in a regional hospital from January- 
December 2016. Women (n=100 HIV uninfected and n=100 HIV infected) were recruited 
and subdivided into three groups: (a) 1st visit attendees ≤ 34 weeks (n=33), (b) 34-36 
weeks (n =34) and (c) ≥ 37 weeks /birth (n=33) respectively. A structured questionnaire 
was used for data collection. Data were coded and computed onto an excel sheet for 
statistical analysis using SPSS software.
 Results: 
Data from women (n = 24) from 1st visit attendees ≤ 34 weeks and 34-36 weeks subgroups 
indicated that pill count and self-reported data reflected 50% adherence and 46% non-
adherence, being higher in the HIV infected women (75%). Nausea was the commonest 
side effect in all trimesters (79, 2%). Adherence (27.8%) and non-adherence (72.1%) to 
iron, folic acid and calcium supplementation were observed in 176 (88%) women. 
Conclusion: 
Adherence to iron, folic acid and calcium supplementation was low in pregnant women 
receiving antenatal care at the study site. 
Keywords: Iron, folic acid, calcium, Adherence, Anemia, Pregnancy, Supplements. 
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INTRODUCTION
Iron deficiency is the most widespread pathologic cause of anemia in pregnancy [1].  
Globally, particularly in low and middle-income countries (LMICs), it is the commonest 
nutrient deficiency affecting both pregnant women and children [2]. Iron is necessary for 
hemoglobin synthesis and its requirement increases during pregnancy. Therefore, to 
reduce the incidence of anemia, women receive prophylactic iron and folic acid 
supplementation throughout pregnancy and the puerperium [1-3]. Folic acid prevents 
neural tube defects and macrocytic anemia, especially when initiated prior to conception 
and continued in early pregnancy during the neural system development [4].
 In pregnancy, the physiological demands of a growing fetus, changes in red cell volume, 
vomiting and increasing nutrient demand support the need for iron supplementation [5]. 
A decrease in iron stores during pregnancy is accompanied by a significant rise in the 
reticulocyte count (RC) that eventuates in an increase in   erythropoiesis [6]. Therefore, 
the RC may be used to monitor progress after iron supplementation. 
The efficacy and success of any medical intervention such as prophylactic iron-folic acid 
therapy throughout pregnancy is dependent on compliance and adherence to the regimen 
of pill usage.  Compliance describes the degree to which an individual accurately follows 
a medical instruction [3]. 
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The major reason that national iron supplementation programs fail is women’s non-
adherence to pill taking and other factors including health systems [3]. Non-adherence is 
defined as missing two or more doses repeatedly [3].
Furthermore, adherence depends on the woman’s behavior during the antenatal period 
[7]. The concurrent use of other medication affect adherence thereby increasing the 
severity of anemia during pregnancy. It is unknown whether the use of antiretroviral drugs 
during pregnancy increases the severity of anemia [8].  However, a study by Odhiambo 
et al., [9] showed that anti-retroviral therapy including zidovudine improved hemoglobin 
levels over time.
The World Health Organization (WHO) states that approximately 56% and 23% of 
pregnant women in LMICs and in high-income countries are respectively anemic [10], and    
defines anemia as a hemoglobin (HB) concentration of ≤ 11g/dl [11]. In South Africa, 
42.7% of maternal deaths is associated with anemia, irrespective of micronutrient 
(prophylactic iron, folic acid and multivitamins) supplementation [12].  The aim of the 
present study was to establish adherence to prophylactic iron, folic acid and calcium 
supplementation among pregnant women in a regional hospital in Durban, South Africa. 
METHODS
This observational clinical study received institutional ethical (BE485/15) and regulatory 
hospital approval. The study was conducted from January- December
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2016 in a regional hospital that serves mainly low socio-economic Black South African 
population group. 
A study population (n=200) consisting of HIV infected (n=100) and uninfected (n=100) 
women were recruited and stratified into: - a) 1st visit attendees ≤ 34 weeks (n=33), b) 34-
36 weeks (n=34) and c) ≥ 37 weeks /birth (n=33) gestation respectively. Inclusion criteria 
included Black South African women attending their first antenatal clinic, who provided 
written informed consent and were ≥ 18 years of age. Women with medical complications 
such as cardiac, diabetes, hypertension and hematological disease were excluded. 
It is a standard clinical practice in South African public sector hospitals that all pregnant 
women receive prophylactic iron and folate supplementation throughout pregnancy. All 
participants received a month’s supply of iron “pregamal” tablets (a combination of ferrous 
fumarate 200mg and folic acid 100mg) at every antenatal visit.  For anemic women, 
ferrous sulphate (FSO4; 200mg) and folic acid (5mg/day) was prescribed. In addition, 
women received calcium carbonate supplementation (1250mg/day) as a preventative 
measure against the development of pre-eclampsia. 
Women recruited were followed-up at their next scheduled antenatal visit for adherence. 
They were requested to return the balance of their supplements. Adherence was 
assessed via self-reporting and by manual pill count.  Self-reporting referred to women 
who reported without carrying their containers.  Whereas, pill
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count refers to the number of pills remaining in the container.  All adherence and non-
adherence information, including side effects were obtained at each follow-up visit. 
Full blood count, reticulocyte and serum ferritin tests were analyzed. Demographics 
including clinical data (age, area of residence, social status, HIV and TB information, 
parity,  gestation age, blood pressure, maternal height and weight, urine dipsticks, blood 
results, birth details, dietary habits (types of food, smoking, alcohol consumption, 
recreational drugs and herbal medication), feeding choice and family planning were 
recorded. 
The Statistical Package for the Social Sciences (SPSS Statistics version 24, IBM 
Corporation, New York) was used for analysis. Independent sample t-test and ANOVA 
were used for parametric data. Categorical data are presented using Fisher’s exact Chi-
squared test. Parametric data are expressed as mean ± standard deviation. A p-value 
≤0.05 was considered statistically significant. 
RESULTS
Clinical and demographic data are outlined in Table 1.  Birthweight was significantly 
different between HIV infected and uninfected groups (p = 0.004). Birthweight at 1st visit 
≤ 34 weeks (3.06 ±0.56, 3.21 ±0.45Kg) and ≥ 37 weeks /birth (3.41 ±0.43, 3.15 ±0.40Kg) 
appropriately matched gestational age albeit that it was lower at 34-36 weeks (2.98-± 
0.52 vs 2.86 ±0.62Kg). 
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The hematological, reticulocyte profiling and serum ferritin (SF) levels taken at antenatal 
visits (1st visit attendees ≤ 34 weeks, 34-36 weeks and ≥ 37 weeks/birth groups) are 
shown in table 2. Hemoglobin levels were below the normal reference range for 
pregnancy at 52%, 58%, 50%, 56%, in the HIV uninfected 1st visit attendees ≤ 34 weeks, 
HIV infected 1st visit attendees ≤ 34 weeks, HIV uninfected 34-36 weeks and HIV infected 
34-36 weeks groups respectively.  The uninfected and infected ≥ 37 weeks /birth groups 
showed lower percentages (18%, 33%). Based on HIV status, SF levels were similar 
across all groups. In the HIV uninfected 1st visit attendees ≤ 34 weeks, the RC percentage 
was higher (6%) than normal compared to the other groups (2%, p=0.44). The reticulocyte 
production index (RPI) was significantly higher and within the reference range for the HIV 
uninfected ≥ 37 weeks /birth (1 ± 0.34) compared to the other  groups (0.78% ± 0.41 vs 
0.62 ± 0.24 vs 0.88 ± 0.26 vs 0.82 ± 0.33 vs 0.81 ± 0.37: p=0.0001). Maternal hemoglobin 
levels at delivery were significantly different between groups (p = 0.006).  
After the initial enrolment visit, a loss to follow-up was noted at subsequent visits, 
particularly in the 34-36 weeks group (Table 3). Hematological profiles such as 
hemoglobin and SF as well as reticulocyte data did not differ across groups and were 
within the normal reference range (Table 3). However, the mean RPI for the infected 1st 
attendees (0.77 ± 0.30%) were below the normal reference range (1-2%).
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The percentage of pill count, self-reported adherence and reasons for non-adherence 
across the study groups are outlined in table 4. 
In the groups that were followed–up, a higher percentage returned empty containers 
(50%) compared to those returning 2 or more pills (20.8%) and to those that did not know 
the number of pills remaining in the container (29.1%). These women reported an 
unknown pill number remaining in the container and gave no reason for their non-
adherence. However, in the HIV infected groups there was a higher percentage  that were 
unaware of the pills remaining (41.7%) compared to the HIV uninfected groups (16%). 
The number returning empty containers were lower in the HIV infected (25%) compared 
to the uninfected (75%) groups. Moreover, the groups that were followed–up at ≥ 37 
weeks/birth gestation, the percentage of women unaware of the number of pills remaining 
was higher (67.6 %) compared to those that returned 2 or more pills (10.5%) and to those 
that reported empty containers (27.8%). Women reporting unknown number of pills were 
higher in the HIV uninfected groups compared to the infected (70.2% vs 64.7%). In 
contrast, those that reported no pills remaining were higher in the HIV infected (31.7%) 
compared to the HIV uninfected group (24.1%). In the HIV uninfected groups, there was 
5.4% of two or more pills remaining compared to 3.5% in the HIV infected groups. 
Table 4 shows the reasons for non–adherence within all groups. In the women that were 
followed–up at scheduled visits, nausea was highest (40%), followed by skipped doses 
(32%), dark stools (16%), constipation (16%) and vomiting (4%). Nausea was highest in 
the 1st attendees group compared to 34 – 36 weeks groups
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irrespective of HIV status. Similarly, the women followed–up at ≥ 37 weeks /birth gestation 
had higher percentage of  nausea (39.2%) followed by dark stools (34%), skipped doses 
(15.9%), constipation (14.8%), vomiting (13.6%), heartburn and forgetfulness (2.8%) and 
pill overload (1.7%). 
DISCUSSION 
The present study assessed compliance and adherence of pregnant women to iron, folic 
acid and calcium supplementation at a regional hospital. Our methods of assessment of 
adherence have been utilized by other studies [13-15]. In our study, adherence of pill 
intake was 50% in the follow-up groups. Non-adherence was noted in 20.8% of women 
who had ≥2 pills remaining whilst 29.1% reported an unknown number of pills at follow–
up visits. We report a higher percentage of women with an unknown number of pills 
remaining (41.7%) in the HIV infected compared to the uninfected women. Off note, most 
of the adherence data collected at ≥ 37 weeks/birth gestation was self–reported rather 
than by pill count. A reason for this factor is that some women consulted at 1st visit were 
only followed–up for pill taking at ≥ 37 weeks /birth gestation. Moreover, in the women 
that were consulted at recruitment and birth the percentage of the number of pills 
remaining in both the HIV uninfected and infected women was low (5.4%, 3.5%). 
However, the percentage of women reporting no pills remaining was higher in the HIV 
infected women (31.7%) compared to the uninfected women (25.1%). 
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There was a high percentage of unknown number of pills remaining in both the HIV 
uninfected and infected women (70.2%, 64.7% respectively). Self-reporting may 
overestimate compliance compared to pill count or biochemical methods [14]. In contrast, 
Ibrahim et al., [13] observed that self–reporting (41.1%) was a better indicator of 
adherence compared to pill count (36.7%). However, Bondarianzadeh et al., [15] 
demonstrated that women may falsely report pill taking, confirmed by positive stool tests. 
Off note, we observed that women were occasionally issued inadequate iron tablet 
supplements until the follow-up visit. This may be attributed to poor antenatal attendance, 
incorrect follow-up dates and the absence of an effective logistic system to dispense the 
supply, or the shortage of drug supply from the institution. A study from another LMIC viz. 
Ethiopia also reported inadequate iron supplementation at antenatal clinic visits due to 
poor iron tablet supplies and the lack of an effective distribution system [14].
In the current study, the reasons for non–adherence to iron prophylactic therapy included 
nausea, vomiting, dark-colored stools, constipation, heartburn, skipped doses, 
forgetfulness and pill overload. In the HIV infected compared to the uninfected group, 
nausea (40% vs 39.2%) was the most common side effect followed by dark stools (16% 
vs 34%), constipation (16% vs 14.8%), skipped doses (32% vs 15.9%), vomiting (4% vs 
13.8%). Similarly, other studies have corroborated our findings of the commonest adverse 
event being nausea [16-18].  In contrast to
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our study, dark stools were not frequently noted in similar studies [16-18].  A high level of 
pregnancy induced nausea and/or vomiting may exacerbate a women’s adherence during 
the first trimester [19]. In our study, the incidence of nausea was high across all trimesters.  
This may be a side effect attributed to the poor quality of iron supplements or due to the 
high level of iron intake on an empty stomach; the latter is corroborated by the low socio–
economic status of the women in our study [20]. Notably, side effects are not associated 
with non–compliance [21].
In the current study, anemia was higher in the HIV infected groups compared to the 
uninfected groups, being higher at 34-36 weeks compared to the term/birth group.  
Similarly, Tunkyi and Moodley  [10] observed a high incidence of anemia in HIV infected 
pregnant women. 
The significant improvement of hemoglobin level at delivery from 1st visit attendees to ≥ 
37 weeks/birth groups in the current study is corroborated by a study conducted in India 
[20]. Anemia prevalence in the latter study was reduced from 48% at 1st visit attendees, 
to 10% at 4th visit. Our findings also reveal that women enter pregnancy having 
inadequate bone marrow response. There was a significant decrease in the production 
of red blood cells within our study population. The RPI levels were significantly different 
(p=0.0001) across groups. In addition, in the HIV uninfected 1st visit group, the mean RC 
was higher compared to the other groups.  These data indicates an immature release of 
red blood cells from the bone marrow and probably accounts for the premature labor 
(13%) and iron deficiency anemia. Despite a
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similar reticulocyte levels across the four groups (p ˃0.05), RPI in the HIV infected 1st visit 
follow–up groups suggest an inadequate bone marrow response. 
 
In the current study, age and socio economic income did not correlate with adherence to 
iron supplementation. Similarly, Roy et al.,[22] showed that age and socio-economic 
status did not correlate whilst Mithra et al.,  [3] suggest parity as a key contributor in iron 
supplementation compliance. 
In addition, the current study demonstrates that iron supplementation is not associated 
with poor birth outcomes such as low birth weight, prematurity and small-for-gestational 
age infants. A study conducted in Tanzania [23] also demonstrates its non-correlation 
with low birth weight, prematurity and small-for-gestational age babies. 
 The limitation of the current study was the lack of follow-up visits. After the initial 
enrolment visit, many women did not return, particularly in the 34-36 weeks group hence 
adherence data was collected only at the time of delivery. A few women delivered in other 
health centers and some may have visited other health facilities or missed scheduled 
dates during antenatal period. Furthermore, incomplete laboratory results had an impact 
on adherence data, mainly during follow–up visits. Thirty three percent of women with 
incomplete results were eliminated at follow–up visit. Lastly, we relied mostly on self–
reported data than pill count and a loss to follow–up contributed to this limitation. 
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The findings from the current study were similar to those from other LMIC countries; side 
effects were the most common reasons for non–adherence to iron prophylactic treatment. 
Furthermore, the RPI might be useful in measuring the bone marrow response and 
response to treatment.  
 Health education sessions are recommended to improve women’s understanding of the 
importance of iron prophylactic therapy including visiting the clinic on scheduled dates. 
Further research should include an electronic counting device for accurate pill count 
including the addressing of concurrent usage of iron prophylactic therapy with other 
treatments.
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           Table 1: Clinical and demographic data of all study groups.










≥ 37 weeks /birth 
HIV uninfected





















Maternal Age (yrs.) 24 ± 5 28 ± 7 25 ± 5 31 ± 6 27 ± 7 30 ±6 0.0001
Maternal height (cm) 158 ± 6 159 ± 7 159 ± 7 157 ± 5 160 ± 7 158 ± 7 0.54
Maternal wt. (kg) 69 ± 16 66 ± 12 76 ± 13 76 ± 17 80 ± 16 84 ± 18 0.0001
BMI (kg/m2) 28 ± 6 27 ± 5 30 ± 5 30 ± 6 32 ± 6 34 ± 6 0.0001
Systolic pressure (mmHg) 12 0 ± 13 115 ± 14 112 ± 10 111 ± 12 112 ± 9 111 ± 11 0.01
Diastolic pressure (mmHg) 70 ± 10 70 ±12 70 ± 9 70 ±11 71 ± 8 70 ± 7 0.1
Parity 0 ± 1 1 ± 1 1 ± 1 1 ± 1 1 ± 1 1 ± 1 0.0001
Gravidity 2 ± .755 2 ± 2 3 ± 2 3 ± 0.9 3 ± 2  3 ± 1 0.0001
GA (wks.) current visit 19 ± 7 20 ± 7 35 ± 0.72 35 ± 2 39 ± 2 38 ± 1 0.0001
GA at birth 38 ± 2 39 ± 2 39 ± 2 39 ± 2 40 ± 2 39 ± 2 0.019
Baby wt. (kg) 3.06 ± 0.56 3.21 ± 0.45 2.98 ± 0.52 2.86 ± 0.62 3.41 ± 0.43 3.15 ± 0.40 0.004
NVD (%) 
Scheduled C/S (%)
Emergency C/S (%) 
54.5
            18.1
              0
      33.3 
      18.1 
      3.0
50 
             14.7
               9
       32.3
       14.7
       23.6
        27.2 
        15.1 
        42.4
      27.2
        9 
     48.4 0.67
Male/Female ratio (%) 45:27 24:30 28:44 29:44 52:33 48:39 0.23
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             21
         79
         21
             76
             24
         59
         41
            91
            9
           52
           48
    0.003
Mean ±SD; NVD – Normal vaginal delivery, C/S – Caesarian section, FSB – Fresh still birth, MSB – Macerated still birth, NND – Neonatal death, 
CPD – Cephalopelvic disproportion, FD – Foetal distress, PE -  Preeclampsia, GA – Gestational age, Kg – Kilograms, Wks. – Weeks CM – 
Centimeters, YRS - years .
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Table 2: Hematological results of all study groups 
1st attendees 















≥ 37 weeks 
/birth 
infectedParameters






at recruitment  
(g/dL) %
11 ± 2 (51.5) 11 ± 2 (57.5) 11 ± 2 (52.9) 11 ± 2 (55.8) 12 ± 2 
(18.1)
12 ± 2 (33.3) 11 - 12 0.0001
Serum ferritin 
(µg/L)
34 ± 35 28 ± 29 30 ± 42 23 ± 15 33 ± 20 30 ± 22 10 - 291 0.68
Reticulocyte C 
(%)
6 ± 23 2 ± 0.46 2 ± 0.48 2 ± 0.50 2 ± 0.43 2 ± 0.59 0.5 – 2 0.44
Reticulocyte C 
A      (X 1012/L)
0.06 ± 0.03 0.06 ± 0.04 0.07 ± 0.02 0.08 ± 0.06 0.09 ± 0.1 0. 07 ± 0.03 0.05 - 0.1 0.09
Corrected R C 
(%)
2 ± 0.45 0.10 ± 0.34 2 ± 0.33 2 ± 0.44 2 ± 0.34 2 ± 0.50 0.0001
Reticulocyte P 
I 
0.78 ± 0.41 0.62 ± 0.24 0.88 ± 0.26 0.82 ± 0.33 1 ± 0.34 0.81 ± 0.37 1 - 2 0.0001
Hemoglobin at 
birth (g/dL)
11 ± 0.59 11 ± 2 11 ± 2 11 ± 2 13 ± 0.91 12 ± 0.89 11 - 12 0.006
Mean ±SD
RC – Reticulocyte count, RCA – Reticulocyte count absolute, CRC – Corrected reticulocyte, RPI – Reticulocyte production index.
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Table: 3:  Clinical data collected during pregnancy follow-up 
Parameters 1st attendees ≤ 
34 weeks 
HIV uninfected










N = 10 N = 9 N = 2 N = 3
Maternal Age 
(yrs.)
24 ± 5 27 ± 6 21 ± 0.71 31 ± 3 - 0.06
GA (wks.) 26 ± 8 30 ± 11 38 ± 3 37 ± 2 - 0.08
Maternal wt. (kg) 65 ± 13 77 ± 13 81 ± 37 79 ± 9 - 0.16
Maternal ht. (cm) 158 ± 7 160 ± 6 159 ± 10 153 ± 2 - 0.31
BMI (kg/m2) 26 ± 4 30 ± 5 33 ± 13 33 ± 3 - 0.04
Hemoglobin 
(g/dL)
11 ± 0.72 11 ± 2 11 ± 0.15 11 ± 0.94 11 - 12 0.96
Reticulocyte C 
(%)
2 ± 0.59 2 ± 0.45 2 ± 2 ± 0.35 0.5 – 2 0.31
Reticulocyte CA 
(X 1012/L)   
0.08 ± 0.03 0.14 ± 0.3 0.19 ± 0.06 ± 0.02 0.05 - 0.1 0.66
Corrected R C 
(%)
2 ± 0.47 2 ± 0.4 2 ± 2 ±0.31 - 0.34
Reticulocyte PI 2 ± 0.32 0.77 ± 0.30 1 ± 2 ± 0.31 1 - 2 0.20
Serum ferritin 
(µg/L)
50 ± 52 23 ± 14 18 ± 27 ± 29 10 - 291 0.53
Mean ±SD 
BMI – Body mass index
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Table 4: Pill count and self - reported adherence.
HIV uninfected 
N = 12 
HIV infected
N = 12 
Total % Total No. of women: 24 
Follow up at scheduled dates: 1st attendees ≤ 34 weeks  / 34 – 36 weeks gestation 
Parameters:
Number of women returned 2 or more pills 1 (8.3%) 4 (33.3%) 5 (20.8%)
Number of women returned zero or no pills 9 (75%) 3 (25%) 12 (50%)
Number of women with unknown number of pills remaining 2 (16.7%) 5 (41.7%) 7 (29.1%)
Adherence (50%)
Non-adherence (46%)
Adherence at term birth and at recruitment: 1st attendees ≤ 34 weeks , 34 -36 weeks, ≥ 37 weeks /birth gestation
HIV uninfected
N = 91 
HIV infected
N = 85 
Total % of all groups Total no. of women: 
176 (88%)
Parameters
Number of women returned 2 or more pills 5 (5.4%) 3 (3.5%) 8 (10.5%)
Number of women returned zero pills 22 (24.1%) 27 (31.7%) 49 (27.8%)
Number of women with unknown number of pills remaining 64 (70.2%)  55 (64.7%) 119 (67.6%)
Adherence (27.8%)
Non-adherence (72.1)
Reasons for non – adherence: follow – up groups: 1st attendees ≤ 34 weeks  / 34 – 36 weeks gestation
HIV uninfected
N = 12 
HIV infected
N = 12 
Total % Total no. of women: 24 


























Skipped doses (%) 30 (3) 50 (1) 30 (3) 33 (1)  8 (32%)
Reasons for non – adherence at birth and at recruitment: 1st attendees ≤ 34 weeks / 34 – 36 weeks, ≥ 37 weeks /birth gestation
Factors HIV uninfected
N = 91 
HIV infected
N = 85 



























Skipped doses (%) 18 (19.8) 10 (11.8%) 28 (15.9%)
Forgetfulness (%) 2 (2.2%) 3 (3.5%) 5 (2.8%)





 Anaemia is a   major public health problem globally, and pregnant women are particularly vulnerable. Iron 
deficiency is the most common cause of anaemia and daily intake of iron supplements during pregnancy 
considerably reduces the incidence of maternal anaemia and the risk of low birth weight babies. In low-
middle income countries (LMIC), the incidence of anaemia is 56%, while it is 23% in high-income countries 
(WHO, 2015). In the context of LMIC, nutritional iron deficiency is the leading cause of anaemia in 
pregnancy (Hoque et al., 2009).  In Africa, the prevalence of anaemia   is estimated at 52% (Jafar and 
Zwede, 2014). The Saving Mothers Report (2010 - 2013) states that 40% of maternal deaths in South Africa 
(SA) were associated with anaemia, while Tunkyi and Moodley, 2016 report similar figures in a regional 
hospital in Durban, South Africa. .
 According to WHO (2011) anaemia is defined as a condition in which the number of red blood cells and 
their oxygen-carrying capacity is inadequate to meet the body’s physiologic needs. It is present when the 
haemoglobin (Hb) concentration in the peripheral blood is ≤11 gm/dl (Sabina at al., 2016). Our study 
demonstrates a decrease in haemoglobin levels of above 50% in women that were <37 weeks gestation 
whereas pregnant women ≥37 weeks gestation had less than a 35% decrease. Similar to our study, a 
Cochrane review by Rukuni et al., 2015 found that there is good evidence of improvement in 
haematological indices with iron supplementation in pregnancy. 
Moreover, we report a significant decrease in the production of red blood cells in the pregnant women 
studied. The reticulocyte production index (RPI) shows a significance difference of p=0.0001 across all the 
groups. Women enter pregnancy having inadequate bone marrow response. A low reticulocyte count with 
low RBCs, low hemoglobin, and low hematocrit may be associated with iron deficiency anemia (American 
Association for Clinical Chemistry, 2001-2017 https:// labtestsonline.org/understanding/ accessed 12th June 
2017). 
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In addition, in the HIV uninfected 1stvisit ≤ 34 weeks group the mean reticulocyte count was higher 
compared to the other groups (6±23 units). The red blood cells are prematurely released from the bone 
marrow into the blood stream, due to a high physiologic demand for iron. Only a limited number of women 
in our study population were followed–up at scheduled visits hence our results display no statistical 
differences on haematology and reticulocyte levels between the four groups (p ˃0.05). However, the mean 
reticulocyte production index of the HIV infected 1st visit  ≤ 34 weeks follow–up groups indicated an 
inadequate bone marrow response. The reticulocyte production index in the other follow-up groups was 
within the normal reference range and indicate a response to iron prophylactic therapy. Additionally, we 
noted non-significant difference in serum ferritin levels across our study population probably suggesting 
the presence of underlying anemia of chronic diseases or inflammation. Sahoo et al., 2016 indicated that 
50% patients had increased serum ferritin, 40% normal and 10% decrease. Therefore, it is recommended 
that serum ferritin should not be used in a single measurement as a marker for iron stores. 
The need for iron and folic acid increases during pregnancy because of the demands of a growing fetus. In 
2012, the World Health Assembly Resolution recommended a broad implementation strategy for maternal, 
infant and young child nutrition, which stated six global nutrition targets that covers a 50% reduction of 
anaemia in women of reproductive age by 2025 (WHA, 2014). The current World Health Organization 
(WHO) guidelines endorse provision of a daily prophylactic oral dose of iron (30-60 mg) and folic acid 
(400 mg) to all pregnant women, initiated at an early stage of pregnancy. The use of iron and folic acid 
supplements during pregnancy are reported to have an impact in reducing maternal anaemia (Nisar and 
Dibley, 2016). 
 Numerous studies have shown that despite the use of a supplementation program, iron deficiency anaemia 
is still common during pregnancy (Cogswell et al., 2014; Ogundipe et al., 2012; Bilimale et al., 2010; 
Ibrahim et al., 2011). 
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However, other studies disagree with this statement (Abdullahi et al., 2014; Nisar et al., 2016). A major 
reason for the failure of national iron supplementation programs is said to be a woman’s non-adherence to 
pill taking.  In our study, adherence was assessed via self-reports and manual pill count by the women in 
the study. Similarly, Ibrahim et al., 2011; Lutsey et al., 2007; Gebremedhin et al., 2014  adopted methods 
for adherence via self-reporting and pill counting. We also found that women were intermittently issued 
supplements that were inadequate to cover a one –month period or until their next clinic date. This could 
be due to their poor attendance to clinic appointments, the absence of effective logistic systems to dispense 
the supply or the lack of drug supplies. Furthermore the poor quality of iron tablets from some 
pharmaceutical suppliers, may lead to nausea and vomiting and therefore poor adherence to pill taking. 
Gebremedhin et al., 2014 observed that nearly half of antenatal care attendees were not given iron 
supplements due to poor iron supply and lack of effective distribution system. We found that adherence of 
pill intake was 50% in the follow-up groups. Non-adherence was noted in 20.8% of women who had ≥2 
pills remaining whilst 29.1% reported an unknown number of pills at follow–up visits.
 We also report a higher percentage of women with an unknown number of pills remaining (41.7%) in the 
HIV infected compared to the uninfected women. However, the percentage of women reporting no pills 
remaining was higher in the HIV infected group (31.7%) compared to the uninfected group (25.1%). 
Moreover, there was a higher percentage of unknown pills remaining in both uninfected and infected 
women (70.2%, 64.7% respectively). Most of the adherence data collected at ≥ 37 weeks/birth gestation 
was self–reported rather than by pill count. A reason for this feature is that some women recruited at their 
1st visit: ≤ 34 weeks were only followed–up for pill taking at ≥ 37 weeks /birth gestation. Several studies 
found that self–reporting overestimates compliance as compared with pill counting or biochemical methods 
(Gebremedhin et al., 2014). 
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These studies report a 75% level of compliance based on the self-reporting method. A study by Ibrahim et 
al., (2011) reflected 58.9% non-adherence and 41.1% adherence (self-reporting) whereas 63.3% of non-
adherence and 36.7% adherence reflected by pill count.  In addition, Lutsey et al., (2007) also confirms 
85% consumption of pills that were self- reported whereas pill count suggested 70%.
The present study also assessed reasons for non-adherence to iron prophylactic supplementation in antenatal 
care attendees. Nausea (40% vs 39.2%) was found to be a common problem across all trimesters, followed 
by dark-coloured stools (16% vs 34%), constipation (16% vs 14.8%), skipped doses (32% vs 15.9%) and 
vomiting (4% vs 13.8%) in the HIV infected and uninfected women respectively; heartburn, forgetfulness 
and pill overload had lower percentages . . Similarly, Bresani et al., 2013, report that the three commonest 
adverse events were nausea (25.8%) and constipation (17.2%). In addition, Kalimbiri et al., (2009), report 
that nausea (43.6%) was the commonest problem in their study.   In a study by Panda et al., 2015, nausea 
(24%) and vomiting (26%) were the most common reasons observed followed by heartburn (10%), diarrhea 
(8%), constipation (6%), abdominal pain (4%) and forgetfulness (24%). In contrast, Mithra et al., 2014 
found forgetfulness (48.8%) followed by vomiting (47.69%), constipation (21.54%) and gastritis (13.84%) 
as common. In contrast, Ibrahim et al., (2011) report frustration from the large pill intake (54.35%) as the 
most common reason for non-adherence. 
The current study revealed that iron supplementation is not associated with poor birth outcome such as low 
birth weight, prematurity and small for gestational age infants. The mean birth weight at 1st visits ≤ 34 
weeks and ≥ 37 weeks/birth groups matched the gestational age regardless of HIV status, whilst the 34-36 
weeks groups were slightly lower for gestational age (2.98-± 0.52 vs 2.86 ±0.62Kg). Other authors have 
also found no association of iron supplementation to low birth weight, prematurity and small-for-
gestational-age neonates (Etheredge et al., 2015).  
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In addition, demographic characteristics such as age and socio economic income do not correlate with 
adherence to iron prophylactic supplementation. Similar to our study, age and socio-economic status are 
not associated with iron prophylactic supplementation (Roy et al., 2013). However, Mithra et al., (2014), 
report that age, socio–economic status and parity are key contributors towards iron supplementation 
compliance. 
Summary and Recommendations 
The findings from the current study were similar to those from other LMIC countries; side effects were the 
most common reasons for non–adherence to iron prophylactic treatment. Furthermore, the RPI might be 
useful in measuring the bone marrow response and response to treatment.  
 Health education sessions are recommended to improve women’s understanding of the importance of iron 
prophylactic therapy including visiting the clinic on scheduled dates. 
Further research should include an electronic counting device for accurate pill count including the 





Abdullahi H, Gasim GI, Saeed A, Imam AM, Adam I. Antenatal iron and folic acid supplementation use 
by pregnant women in Khartoum, Sudan. BMC research notes 2014; 7(1): 1-4.
American association for clinical chemistry, Reticulocytes 2001-2017. 
https://labtestsonline.org/understanding/analytes/reticulocyte/tab/test/ (Accessed on 12 June 2017). 
Beard JL. Effectiveness and strategies of iron supplementation during pregnancy. The American Journal of 
Clinical Nutrition 2000; 71(5): 1288-1294.
Bekele A, Tilahun M, Mekuria A. Prevalence of anemia and its associated factors among pregnant 
women attending antenatal care in health institutions of Arba Minch Town, Gamo Gofa Zone, Ethiopia: a 
cross-sectional study. Anemia 2016; 2016: 1-9.
Bilimale A, Anjum J, Sangolli HN, Mallapur, M. Improving Adherence to Oral Iron Supplementation 
during pregnancy. Australasian Medical Journal 2010; 3(5): 281-290.
Cogswell ME, Parvanta I, Ickes L, Yip R, Brittenham GM. Iron supplementation during pregnancy, anemia, 
and birth weight: a randomized controlled trial. The American Journal of Clinical Nutrition 2003; 78(4): 
773-781.
Burke RM, Leon JS, Suchdev PS. Identification, prevention and treatment of iron deficiency during the 
first 100 days. Journal of Nutrients 2014; 6: 4093-4110.
Cantor AG, Bougatsos C, Dana T, Blazina I, McDonagh M. Routine Iron Supplementation and Screening 
for Iron Deficiency Anemia in Pregnancy: A Systematic Review for the US Preventive Services Task Force 
Iron Supplementation and Screening for Iron Deficiency Anemia in Pregnancy. Annals of Internal Medicine 
2015; 162(8): 566-576. 
Cases of anaemia. http://www.meddean.luc.edu/lumen/meded/mech/cases/case7/anemia.htm (accessed 09 
June 2016). Pp 1-7.
47
Ehiaghe FA, Enwa OF, Akinshipe BO, Ikusemoro AI. Reticulocyte assessment as a biomarker for bone 
marrow erythropoietic function in pregnant women attending antenatal clinic in Benin City, Nigeria. 
Journal of Advances in Biology 2014, 4(1): 318-321.
Erhabor O, Isaac IZ, Isah A, Udomah FP. Iron deficiency anaemia among antenatal women in Sokoto, 
Nigeria. British Journal of Medical and Health Sciences. 2013; 1(4): 47-57.
Etheredge AJ, Premji Z, Gunaratna NS, Abioye AI, Aboud S, Duggan C, Mongi R, Meloney L, Spiegelman 
D, Roberts D, Hamer DH,. Iron supplementation in iron-replete and nonanemic pregnant women in 
Tanzania: a randomized clinical trial. JAMA Pediatrics 2015 169(10): 947-955.
Gebremedhin S, Samuel A, Mamo G, Moges T, Assefa T. Coverage, compliance and factors associated 
with utilization of iron supplementation during pregnancy in eight rural districts of Ethiopia: a cross-
sectional study. BMC Public Health 2014; 14(1): 1-8.
Gersten T Medline plus. http://www.nlm.nih.gov/medlineplus/ency/article/003490.htm (accessed 01 July 
2016). Pp 1-4.
Haemoglobin – complete blood count. http://www.rnceus.com/cbc/cbchg.html 2013; (accessed 01 July 
2016). Pp 1-2.
Health questions NHS Choices. Why do I need folic acid in pregnancy? 
http://www.nhs.uk/chq/pages/913.aspx?categoryid=54 (accessed 05 July 2016). 
Hodgetts VA, Morris RK, Francis A, Gardosi J, Ismail KM. Effectiveness of folic acid supplementation in 
pregnancy on reducing the risk of small-for-gestational age neonates: a population study, systematic review 
and meta-analysis. British Journal of Obstetrics and Gynaecology 2014; DOI: 10.1111/1471-0528.13202: 
1-13.
Hoque M, Hoque E, Kader SB. Risk factors for anaemia in pregnancy in rural KwaZulu-Natal, South 
Africa: Implication for health education and health promotion. South African Family Practice 2009; 51(1): 
68-72.
48
Hyder SMZ, Persson LA, Chowdhury AMR, Ekström E. Do Side-effects Reduce Compliance to Iron 
Supplementation? A Study of Daily- and Weekly-dose Regimens in Pregnancy. Journal of Health and 
Population Nutrition 2002; 20(2): 175-179.
Ibrahim ZM, EL-Hamid SA, Mikhail H, Khattab MS. Assessment of Adherence to Iron and Folic Acid 
Supplementation and Prevalence of Anemia in Pregnant Women. The Medical Journal of Cairo University, 
2011; 79(2): 115-121.
Iron in diet. University of Maryland medical centre.  http://umm.edu/health/medical/ency/articles/iron-in-
diet (accessed 0n 01 July 2016). Pp 1-5 
Jasti S, Siega-Riz AM, Cogswell ME, Hartzema AG, Bentley ME. Pill count adherence to prenatal 
multivitamin/mineral supplement use among low-income women. The Journal of Nutrition 2005; 135(5): 
1093-1101.
Jufar AH, Zewde T. Prevalence of anemia among pregnant women attending antenatal care at tikur anbessa 
specialized hospital, Addis Ababa Ethiopia. Journal of Hematology & Thromboembolic Diseases 2014; 2: 
1-6.
Kalimbira AA, Mtimuni BM, Chilima DM. Maternal knowledge and practices related to anemia and iron 
supplementation in rural Malawi: A cross-sectional study. African Journal of Food Agriculture Nutrition 
and Development 2009; 9(1): 550-564.
Lutsey PL, Dawe D, Villate E, Valencia S, Lopez O. Iron supplementation compliance among pregnant 
women in Bicol, Philippines. Public Health Nutrition 2008; 11(01): 76-82.
Mamabolo RL, Alberts M. Prevalence of anaemia and its associated factors in African children at one and 
three years residing in the Capricorn District of Limpopo Province, South Africa. 
Doi:110.4102/Curationis.v37i1.1160 2014; 37(1): 1-9.
Milman N. Anemia Still a major health problem in many parts of the world! Annals of Hematology 2011; 
90(4): 370-377.
49
Mithra P, Unnikrishnan B, Rekha T, et al. Compliance with iron-folic acid (IFA) therapy among pregnant 
women in an urban area of south India. African Health Sciences 2014; 14(1): 255-260.
Nandlal V, Moodley D, Grobler A, Bagratee J, Maharaj NR, Richardson P. Anemia in pregnancy is 
associated with advanced HIV disease. PloS One 2014; 9(9): p1-6.
Nisar YB, Dibley MJ. Iron/folic acid supplementation during pregnancy prevents neonatal and under-five 
mortality in Pakistan: propensity score matched sample from two Pakistan Demographic and Health 
Surveys. Global Health Action 2016; 9: 1-15.
Nwaru BI, Salomé G, Abacassamo F, et al. Adherence in a pragmatic randomized controlled trial on 
prophylactic iron supplementation during pregnancy in Maputo, Mozambique. Public Health Nutrition 
2015; 18(06): 1128-1134.
Ogundipe O, Hoyo C, Østbye T, Oneko O, Manongi R, Lie RT, Daltveit, AK. Factors associated with 
prenatal folic acid and iron supplementation among 21,889 pregnant women in Northern Tanzania: a cross-
sectional hospital-based study. BMC Public Health 2012; 12(1): 1-10.
Osungbade KO, Oladunjoye AO. Anaemia in developing countries: burden and prospects of prevention and 
control. InAnemia 2012: 115-128.
Panda BK, Taralekar VS, Mishra A, Srivastava P. Anemia in pregnancy: Improving adherence with 
interventions. Biopharm Journal 2015; 1(1): 33-40.
Parkkali S, Abacassamo F, Nwaru BI, Salomé G, Augusto O, Regushevskaya E. Comparison of routine 
prenatal iron prophylaxis and screening and treatment for anaemia: pregnancy results and preliminary 
birth results from a pragmatic randomised controlled trial (PROFEG) in Maputo, Mozambique. BMJ open 
2013; 3(2): 1-9.
Patient information leaflet, ferrous sulphate 200mg (https://www.medicines.org.uk/emc/medicine/18081 
(accessed 05 July 2016). Pp 1-4.
Roy MP, Mohan U, Singh SK, Singh VK, Srivastava AK. Socio-economic determinants of adherence to 
iron and folic acid tablets among rural antenatal mothers in Lucknow, India. National Journal of Community 
Medicine 2013; 4(3): 386-391.
50
Rukuni R, Knight M, Murphy MF, Roberts D, Stanworth SJ. Screening for iron deficiency and iron 
deficiency anaemia in pregnancy: a structured review and gap analysis against UK national screening 
criteria. BMC Pregnancy and childbirth 2015; 15(1): 1-11. 
Sabina S, Iftequar S, Zaheer Z, Khan MM, Khan S. An overview of anemia in pregnancy. J Innov Pharm 
Biol Sci 2015; 2: 144-151.
Sahoo N, Nayak, M, Sahoo PN, Gharei RM, Roul B, Dash AK. Haematological profile, serum iron and 
ferritin level in Anaemia of Inflammation. Based Med,Healthc 2016; 3: 3262-3269.
Sambili B,  Kimambo R,  Peng Y,  Ishunga E,  Matasha E, Matumu G, et al. Factors Influencing Anti-
Malarial Prophylaxis and Iron Supplementation Non-Compliance among Pregnant Women in Simiyu 
Region, Tanzania. International Journal of Enviromental Research and Public Health 2016; 13: 1-12.
Sangwan K, Kumar N, Jindal HA, Jitendra, Bhatt B, Sahoo SS, et al. Socio demographic determinants of 
IFA intake during pregnancy among mothers in rural area of Rohtak, Haryana, India. International 
Journal of Basic and Applied Medical Sciences 2014; 4(3): 49-56. 
Taye B, Abeje G, Mekonen A. Factors associated with compliance of prenatal iron folate supplementation 
among women in Mecha district, Western Amhara: a cross-sectional study. Pan African Medical Journal 
2015; 20(1): 1-7.
Tunkyi K, Moodley J. Prevalence of anemia in pregnancy in a regional health facility in South Africa.  
South African Medical Journal 2016; 106(1): 101-104.
World Health Organization guideline: Daily iron and folic acid supplementation in pregnant women. 
Geneva, World Health Organization 2012; pp 1-27.
World Health Organization and Targets WGN. Anaemia Policy Brief. Geneva: World Health Organization 
2014-2025 http://www.who.int/nutrition/topics/globaltargets_anaemia_policybrief.pdf (accessed 24 May 
2017). Pp 1-7.
WHO, 2015 http://apps.who.int/iris/bitstream/10665/177094/1/9789241564960_eng.pdf (accessed 24 May 
2017).
51
World Health Organization, 2015. Haemoglobin concentrations for the diagnosis of anaemia and 
assessment of severity. Geneva: WHO Google Scholar. 2011.
Human iron metabolism – Wikipedia. https://en.wikipedia.org/wiki/Humam_iron_metaboilism (accessed 
01 July 2016). Pp 1-11.
Van Bogaert LJ. Anaemia and pregnancy outcomes in a South African rural population. Journal of 
obstetrics and gynaecology. 2006; 26(7): 617-619.
52
APPENDIX
53
54
